IP Library Granted Patent US 7,498,156
Granted Patent B2
US 7,498,156 · App. 11/154,503 · Granted Mar 3, 2009

Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,498,156
App. No.
11/154,503
Granted
Mar 3, 2009
Kind
B2
Abstract

This invention is directed towards a method of using visible light at wavelengths of at least 500 nm and above in combination with a sensitizer having a flavin moiety to reduce any pathogens that may be contained in blood and blood components. By exposing the blood and blood components to light of 500 nm and higher, only the sensitizer that is bound to nucleic acids of the pathogens will be activated, thus destroying the sensitizer-pathogenic nucleic acid complex. Because unbound sensitizer is not activated at this wavelength, damage to blood and blood components caused by photolysis of unbound sensitizer may be avoided.

Claims (14)

1. A process for pathogen reduction of a fluid containing blood or blood products which may contain pathogens having nucleic acids comprising:

adding to the fluid a sensitizer containing a flavin moiety;

allowing the sensitizer to bind to the nucleic acid of the pathogens to make a fluid having bound sensitizer and unbound sensitizer; and

irradiating the fluid at a wavelength of 500 nm to 550 nm, wherein only the bound sensitizer is activated and the unbound sensitizer is not activated;

thereby reducing the number of pathogens in the fluid.

2. The process of claim 1 wherein the sensitizer containing a flavin moiety is an alloxazine.

3. The process of claim 2 wherein the alloxazine is riboflavin.

4. The process of claim 1 , wherein the step of adding sensitizer further comprises adding sensitizer in a concentration between 50 μM and 200 μM.

5. The process of claim 1 wherein the fluid further comprises red blood cells.

6. The process of claim 1 wherein the fluid further comprises platelets.

7. The process of claim 1 wherein the fluid further comprises plasma.

8. The process of claim 1 wherein the step of irradiating further comprises removing light at wavelengths below 500 nm.

9. The process of claim 8 wherein the step of irradiating further comprises removing light at wavelengths above 525 nm.

10. The process of claim 8 wherein the step of irradiating further comprises removing light at wavelengths above 550 nm.

Assignments (7)
CHANGE OF NAME Recorded Feb 16, 2012
From: CARIDIANBCT BIOTECHNOLOGIES, LLC
To: TERUMO BCT BIOTECHNOLOGIES, LLC.
Reel/Frame 027715/0649 →
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2011
From: CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT
To: CARIDIANBCT BIOTECHNOLOGIES, LLC
Reel/Frame 026192/0547 →
SECURITY AGREEMENT SUPPLEMENT Recorded Jul 16, 2010
From: CARIDIANBCT BIOTECHNOLOGIES, LLC
To: CITICORP TRUSTEE COMPANY LIMITED, AS SECURITY AGENT
Reel/Frame 024686/0972 →
IP SECURITY AGREEMENT SUPPLEMENT Recorded May 21, 2009
From: CARIDIANBCT BIOTECHNOLOGIES, LLC
To: CITICORP TRUSTEE COMPANY LIMITED
Reel/Frame 022714/0560 →
CHANGE OF NAME Recorded Jul 28, 2008
From: NAVIGANT BIOTECHNOLOGIES, LLC
To: CARIDIANBCT BIOTECHNOLOGIES, LLC.
Reel/Frame 021301/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2005
From: GOODRICH, RAYMOND P.
To: NAVIGANT BIOTECHNOLOGIES, INC.
Reel/Frame 016924/0955 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2005
From: PLATZ, MATHEW S.; MARTIN, CHRISTOPHER B.
To: OHIO STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 016924/0959 →